FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4212882007> ?p ?o ?g. }

• W4212882007 abstract "The effects of levothyroxine (LT4)/liothyronine (LT3) combination therapy on quality of life (QoL) in hypothyroid patients former on LT4 monotherapy have been disappointing. We therefore wanted to test the effects of LT3 monotherapy on QoL in hypothyroid patients with residual symptoms despite thyroid stimulating hormone (TSH) values within the reference range.Female hypothyroid patients with residual symptoms on LT4 monotherapy or combination LT4/LT3 therapy received LT3 and LT4 monotherapy, respectively for 12 weeks in a non-blinded randomized crossover study.Fifty-nine patients aged 18-65 years were included. QoL was assessed using one disease-specific questionnaire (ThyPRO) and two generic questionnaires (Fatigue Questionnaire and SF-36) at baseline and at the end of the two treatment periods. Clinical indices of cardiovascular health (resting heart rate and blood pressure), as well as thyroid tests, were assessed at baseline and at the end of the two treatment periods.After 12 weeks of LT3 treatment, 12 of the 13 domains of the ThyPRO questionnaire (physical, mental and social domains) showed significant improvements. The most pronounced improvements were less tiredness (mean -21 ± 26; P<0.0001) and cognitive complaints (mean -20 ± 20; P<0.0001). LT4 monotherapy exerted minor effects on two domains only (cognitive complaints and impaired daily life). All three dimensions' scores in the Fatigue Questionnaire (physical, mental and total fatigue) improved after LT3 treatment compared to baseline (P<0.001), and in the SF-36 questionnaire 7 of 8 scales showed significantly better scores after LT3 treatment compared to baseline. There were no differences in blood pressure or resting heart rate between the two treatment groups. TSH in patients on LT3 was slightly higher (median 1.33 mU/L (interquartile range (IQR) 0.47-2.26)) than in patients on LT4 (median 0.61 mU/L (IQR 0.25-1.20; P<0.018). Five patients on LT3 dropped out of the study due to subjectively reported side effects, compared to only one on LT4.LT3 treatment improved QoL in women with residual hypothyroid symptoms on LT4 monotherapy or LT4/LT3 combination therapy. Short-term LT3 treatment did not induce biochemical or clinical hyperthyroidism, and no cardiovascular adverse effects were recorded. Further studies are needed to assess the long-term safety and efficacy of LT3 monotherapy.ClinicalTrials.gov, identifier NCT03627611." @default.
• W4212882007 created "2022-02-24" @default.
• W4212882007 creator A5011542979 @default.
• W4212882007 creator A5020408351 @default.
• W4212882007 creator A5035849379 @default.
• W4212882007 creator A5061396630 @default.
• W4212882007 creator A5063560085 @default.
• W4212882007 creator A5067955208 @default.
• W4212882007 creator A5074326494 @default.
• W4212882007 date "2022-02-22" @default.
• W4212882007 modified "2023-10-10" @default.
• W4212882007 title "Effect of Liothyronine Treatment on Quality of Life in Female Hypothyroid Patients With Residual Symptoms on Levothyroxine Therapy: A Randomized Crossover Study" @default.
• W4212882007 cites W1490058975 @default.
• W4212882007 cites W1747119434 @default.
• W4212882007 cites W178768211 @default.
• W4212882007 cites W1968810407 @default.
• W4212882007 cites W1991905139 @default.
• W4212882007 cites W1997047813 @default.
• W4212882007 cites W2004435509 @default.
• W4212882007 cites W2010803720 @default.
• W4212882007 cites W2016594484 @default.
• W4212882007 cites W2040054848 @default.
• W4212882007 cites W2057697685 @default.
• W4212882007 cites W2073842601 @default.
• W4212882007 cites W2108263652 @default.
• W4212882007 cites W2110647490 @default.
• W4212882007 cites W2112802342 @default.
• W4212882007 cites W2117756761 @default.
• W4212882007 cites W2120786909 @default.
• W4212882007 cites W2120985321 @default.
• W4212882007 cites W2123438362 @default.
• W4212882007 cites W2127290117 @default.
• W4212882007 cites W2127811896 @default.
• W4212882007 cites W2135039498 @default.
• W4212882007 cites W2140933987 @default.
• W4212882007 cites W2151464162 @default.
• W4212882007 cites W2163234542 @default.
• W4212882007 cites W2163820892 @default.
• W4212882007 cites W2165188459 @default.
• W4212882007 cites W2166169840 @default.
• W4212882007 cites W2171720443 @default.
• W4212882007 cites W2171876114 @default.
• W4212882007 cites W2315033586 @default.
• W4212882007 cites W2331609984 @default.
• W4212882007 cites W2344105416 @default.
• W4212882007 cites W2347201063 @default.
• W4212882007 cites W2542430691 @default.
• W4212882007 cites W2981174073 @default.
• W4212882007 cites W3215985669 @default.
• W4212882007 doi "https://doi.org/10.3389/fendo.2022.816566" @default.
• W4212882007 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35273566" @default.
• W4212882007 hasPublicationYear "2022" @default.
• W4212882007 type Work @default.
• W4212882007 citedByCount "5" @default.
• W4212882007 countsByYear W42128820072022 @default.
• W4212882007 countsByYear W42128820072023 @default.
• W4212882007 crossrefType "journal-article" @default.
• W4212882007 hasAuthorship W4212882007A5011542979 @default.
• W4212882007 hasAuthorship W4212882007A5020408351 @default.
• W4212882007 hasAuthorship W4212882007A5035849379 @default.
• W4212882007 hasAuthorship W4212882007A5061396630 @default.
• W4212882007 hasAuthorship W4212882007A5063560085 @default.
• W4212882007 hasAuthorship W4212882007A5067955208 @default.
• W4212882007 hasAuthorship W4212882007A5074326494 @default.
• W4212882007 hasBestOaLocation W42128820071 @default.
• W4212882007 hasConcept C126322002 @default.
• W4212882007 hasConcept C142724271 @default.
• W4212882007 hasConcept C159110408 @default.
• W4212882007 hasConcept C168563851 @default.
• W4212882007 hasConcept C1862650 @default.
• W4212882007 hasConcept C187212893 @default.
• W4212882007 hasConcept C204787440 @default.
• W4212882007 hasConcept C27081682 @default.
• W4212882007 hasConcept C2775883008 @default.
• W4212882007 hasConcept C2779951463 @default.
• W4212882007 hasConcept C526584372 @default.
• W4212882007 hasConcept C71924100 @default.
• W4212882007 hasConcept C87813604 @default.
• W4212882007 hasConceptScore W4212882007C126322002 @default.
• W4212882007 hasConceptScore W4212882007C142724271 @default.
• W4212882007 hasConceptScore W4212882007C159110408 @default.
• W4212882007 hasConceptScore W4212882007C168563851 @default.
• W4212882007 hasConceptScore W4212882007C1862650 @default.
• W4212882007 hasConceptScore W4212882007C187212893 @default.
• W4212882007 hasConceptScore W4212882007C204787440 @default.
• W4212882007 hasConceptScore W4212882007C27081682 @default.
• W4212882007 hasConceptScore W4212882007C2775883008 @default.
• W4212882007 hasConceptScore W4212882007C2779951463 @default.
• W4212882007 hasConceptScore W4212882007C526584372 @default.
• W4212882007 hasConceptScore W4212882007C71924100 @default.
• W4212882007 hasConceptScore W4212882007C87813604 @default.
• W4212882007 hasFunder F4320335102 @default.
• W4212882007 hasLocation W42128820071 @default.
• W4212882007 hasLocation W42128820072 @default.
• W4212882007 hasLocation W42128820073 @default.
• W4212882007 hasLocation W42128820074 @default.
• W4212882007 hasOpenAccess W4212882007 @default.
• W4212882007 hasPrimaryLocation W42128820071 @default.
• W4212882007 hasRelatedWork W1560976911 @default.
• W4212882007 hasRelatedWork W2039756825 @default.

• next